• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用析因设计法制备和评价含酮洛芬与尤特奇RL 100的缓释栓剂

The preparation and evaluation of sustained release suppositories containing ketoprofen and Eudragit RL 100 by using factorial design.

作者信息

Ozgüney I, Ozcan I, Ertan G, Güneri T

机构信息

Department of Pharmaceutical Technology, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey.

出版信息

Pharm Dev Technol. 2007;12(1):97-107. doi: 10.1080/10837450701196565.

DOI:10.1080/10837450701196565
PMID:17484149
Abstract

The preparation of ketoprofen (KP) sustained release (SR) suppositories was designed according to the 3(2) x 2(1) factorial design as three different KP:Eudragit RL 100 ratios (1:0.5, 1:1, 1:2), three particle sizes of prepared granules (250-500, 500-710, and 710-1000 microm) and two different PEG 400:PEG 6000 ratios (40:60, 50:50). The conventional KP suppositories were also prepared by using Witepsol H 15, Massa Estarinum B, Cremao and the mixture of PEG 400:PEG 6000. The dissolution studies of suppositories prepared were carried out according to the USP XXIII basket method in the phosphate buffer (pH = 7.2) at 50 rpm, and it was shown that the dissolution time was sustained up to 8 hours. According to the results of the factorial design, the most important independent variable on t50 and t80 was drug:polymer ratios. The log of partition coefficient of KP was determined as 1.46, showing the high affinity to the oily phase. n exponent and kinetic studies were conducted to explain diffusion mechanism, and it is understood that if the inert KP:Eudragit RL 100 ratio is increased in the particles, the Fickian difusion dominates and the best kinetic turns to Higuchi from the Hixson-Crowell. There is neither crystalline form of KP nor degradation product in the suppositories detected with the differential scanning calorimetry (DSC) studies. In addition to these studies, antiinflammatory activity of SR suppositories also determined that it was significantly extended according to the conventional suppositories.

摘要

酮洛芬(KP)缓释栓剂的制备是根据3(2)×2(1)析因设计进行的,涉及三种不同的KP与丙烯酸树脂RL 100比例(1:0.5、1:1、1:2)、三种制备颗粒的粒径(250 - 500、500 - 710和710 - 1000微米)以及两种不同的聚乙二醇400:聚乙二醇6000比例(40:60、50:50)。传统的KP栓剂也采用半合成脂肪酸甘油酯(Witepsol H 15)、淀粉(Massa Estarinum B)、乳膏(Cremao)以及聚乙二醇400:聚乙二醇6000的混合物来制备。所制备栓剂的溶出度研究按照美国药典XXIII桨法在pH = 7.2的磷酸盐缓冲液中以50转/分钟进行,结果显示溶出时间可持续长达8小时。根据析因设计的结果,对t50和t80影响最重要的自变量是药物与聚合物的比例。测定出KP的分配系数对数为1.46,表明其对油相具有高亲和力。进行n指数和动力学研究以解释扩散机制,可以理解的是,如果颗粒中惰性的KP与丙烯酸树脂RL 100比例增加,菲克扩散占主导,最佳动力学从希克森 - 克劳威尔方程转变为 Higuchi 方程。差示扫描量热法(DSC)研究未检测到栓剂中有KP的晶型或降解产物。除了这些研究之外,还测定了缓释栓剂的抗炎活性,结果表明与传统栓剂相比,其抗炎活性显著延长。

相似文献

1
The preparation and evaluation of sustained release suppositories containing ketoprofen and Eudragit RL 100 by using factorial design.采用析因设计法制备和评价含酮洛芬与尤特奇RL 100的缓释栓剂
Pharm Dev Technol. 2007;12(1):97-107. doi: 10.1080/10837450701196565.
2
In vitro-in vivo evaluation of in situ gelling and thermosensitive ketoprofen liquid suppositories.原位凝胶化热敏型酮洛芬液体栓剂的体外-体内评价
Eur J Drug Metab Pharmacokinet. 2014 Dec;39(4):283-91. doi: 10.1007/s13318-013-0157-6. Epub 2013 Oct 6.
3
Evaluation of the sustained release properties of Eudragit RS, RL and S (acrylic resins) microcapsules containing ketoprofen in beagle dogs.含酮洛芬的Eudragit RS、RL和S(丙烯酸树脂)微胶囊在比格犬体内的缓释特性评价。
J Microencapsul. 1988 Oct-Dec;5(4):343-60. doi: 10.3109/02652048809036732.
4
Preparation and evaluation of ketoprofen floating oral delivery system.酮洛芬胃内漂浮型口服给药系统的制备与评价
Int J Pharm. 2001 Jun 4;220(1-2):13-21. doi: 10.1016/s0378-5173(01)00574-9.
5
Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers.难溶性药物从含丙烯酸聚合物的热熔挤出物中的控释。
Drug Dev Ind Pharm. 2006 Jun;32(5):569-83. doi: 10.1080/03639040500528996.
6
Transdermal delivery of ketoprofen: the influence of drug-dioleylphosphatidylcholine interactions.酮洛芬的透皮给药:药物与二油酰磷脂酰胆碱相互作用的影响。
Pharm Res. 2006 Aug;23(8):1776-85. doi: 10.1007/s11095-006-9040-3.
7
In vitro and in vivo evaluations of ketoprofen extended release pellets prepared using powder layering technique in a rotary centrifugal granulator.采用粉末层积技术在旋转离心制粒机中制备酮洛芬控释微丸的体外和体内评价。
Arch Pharm Res. 2011 Jul;34(7):1135-42. doi: 10.1007/s12272-011-0711-1. Epub 2011 Aug 3.
8
Preparation and evaluation of ketoprofen hot-melt extruded enteric and sustained-release tablets.酮洛芬热熔挤出肠溶缓释片的制备与评价
Drug Dev Ind Pharm. 2008 Jan;34(1):83-9. doi: 10.1080/03639040701580572.
9
Preparation and Evaluation of Hot-Melt Extruded Patient-Centric Ketoprofen Mini-Tablets.热熔挤出法制备以患者为中心的酮洛芬迷你片及其评价
Curr Drug Deliv. 2016;13(5):730-41. doi: 10.2174/1567201812666151012113806.
10
Design and In Vivo Anti-Inflammatory Effect of Ketoprofen Delayed Delivery Systems.酮洛芬延迟释放系统的设计及其体内抗炎作用
J Pharm Sci. 2015 Oct;104(10):3451-8. doi: 10.1002/jps.24554. Epub 2015 Jun 18.

引用本文的文献

1
In vitro-in vivo evaluation of in situ gelling and thermosensitive ketoprofen liquid suppositories.原位凝胶化热敏型酮洛芬液体栓剂的体外-体内评价
Eur J Drug Metab Pharmacokinet. 2014 Dec;39(4):283-91. doi: 10.1007/s13318-013-0157-6. Epub 2013 Oct 6.